Compressed tablets containing HMOs
Patent Information
- Application Number
- JP2023526323
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-12
- Filing Date
- 2021-11-26
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Conventional binders used in tablet formulations, such as PVP, sorbitol, and MCC, often cause adverse effects or inconsistencies, limiting their effectiveness and necessitate the development of alternative binders with better binding properties.
Incorporating human milk oligosaccharides (HMOs) into tablet formulations enhances tablet robustness and reduces the need for conventional binders, allowing for lower compression forces and improved tablet hardness.
HMOs provide robust and stable tablets with reduced binder usage, offering health benefits and lower power consumption while maintaining or improving tablet integrity.
Abstract
Description
Detailed Description of the Invention
[0001] The present invention relates to compressed (robust) tablets containing a specific amount of at least one human milk oligosaccharide (HMO).
[0002] The formation and stability of robust tablets depend on the use of binders in the formulation of tablets. Such tablets can be chewable tablets, or regular swallowable tablets, or ODT (orally disintegrating tablets), or any other type of tablets. The use of such tablets is very widespread.
[0003] Many binders, such as PVP (polyvinylpyrrolidone), and diluents with binding capacity, such as sorbitol, mannitol, and MCC (microcrystalline cellulose), have been widely used in dietary supplements and pharmaceutical robust tablet products. However, the use of these binders can often be limited for various reasons. For example, sorbitol has a laxative effect and can cause gastrointestinal symptoms. MCC is water-insoluble and can cause grittiness in chewable tablets and ODTs. Although PVP is a good binder, it is more often used in wet granulation, and when applied as a dry binder for directly compressible tablets, it can cause lot-to-lot variation.
[0004] Therefore, there is a need for alternative binders that have good binding properties but do not have the disadvantages of conventional binders as described above.
[0005] Surprisingly, the use of at least one HMO in a robust tablet results in a very robust tablet and allows for a reduction in the amount of conventional binders.
[0006] Tablet hardness is an important quality factor to ensure that tablets remain intact during coating, rolling, and shipping. Additionally, the use of binders can help reduce power consumption by requiring lower compression forces.
[0007] Surprisingly, it has been found that the use of at least one HMO significantly improves tablet robustness / hardness.
[0008] The use of HMOs can reduce the use of other binders such as sorbitol while at the same time achieving significantly more robust tablets, which in turn can aid in lower compression forces and correspondingly lower power consumption.
[0009] In addition, HMOs have been shown to have a variety of health benefits at different rates of use.
[0010] Thus, the present invention provides a compressed tablet (CT), comprising: (i) at least one binder; (ii) at least 1 wt. % of at least one HMO, based on the total weight of the compressed tablet; and (iii) optionally, at least one additional active ingredient (e.g., a vitamin, a nutritional lipid, a mineral, a carotenoid, a nutraceutical, a glycosaminoglycan or an active member thereof, an amino acid, or a combination thereof, or any other type of dietary ingredient useful for human or animal nutrition (preferably, a vitamin, a mineral, a glycosaminoglycan or an active member thereof); and having a hardness of at least 2 kp.
[0011] 1 kp is 9.80665 Newtons (N).
[0012] In the context of the present invention, the binder is sugars and their derivatives, such as disaccharides (i.e. sucrose, lactose), polysaccharides and their derivatives (i.e. starch, cellulose or modified cellulose (i.e. microcrystalline cellulose) and cellulose ethers, such as hydroxypropyl cellulose (HPC)), sugar alcohols, such as xylitol, sorbitol or mannitol, Proteins (such as gelatin), Synthetic polymers (polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), etc.), Mineral-type binders, such as calcium carbonate and dicalcium phosphate is.
[0013] The present invention therefore relates to a compressed tablet (CT1), wherein at least the binder is selected from the group consisting of sugars and their derivatives, proteins, synthetic polymers and mineral type binders.
[0014] Therefore, the present invention relates to a compressed tablet (CT1') which is a compressed tablet (CT) or (CT1) in which at least the binder is selected from the group consisting of disaccharides (i.e., sucrose, lactose), polysaccharides and derivatives thereof (i.e., starch, cellulose or modified cellulose (i.e., microcrystalline cellulose and cellulose ethers, e.g., hydroxypropyl cellulose (HPC)), sugar alcohols, e.g., xylitol, sorbitol or mannitol), gelatin, polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG)), mineral-type binders, e.g., calcium carbonate and dicalcium phosphate, etc.
[0015] The amount of the at least one binder can vary, with a typical (and preferred) range being 0.5 to 98 wt-% of the at least one binder, based on the total weight of the compressed tablet.
[0016] A range of 20 to 80 wt-% based on the total weight of the compressed tablet is more preferred.
[0017] Therefore, the present invention relates to a compressed tablet (CT2), which is a compressed tablet (CT) or (CT1'), in which the amount of at least one binder is 0.5 to 98 wt-% based on the total weight of the compressed tablet.
[0018] A range of 20 to 80 wt-% based on the total weight of the compressed tablet is more preferred.
[0019] Therefore, the present invention relates to a compressed tablet (CT2'), which is a compressed tablet (CT) or (CT1'), in which the amount of at least one binder is 20 to 80 wt-% based on the total weight of the compressed tablet.
[0020] An essential ingredient of the compressed tablets according to the present invention is one or more HMOs.
[0021] Human milk oligosaccharides (HMOs) are a family of structurally distinct unconjugated glycans that are highly abundant and unique to human breast milk. Originally, HMOs were proposed to be prebiotic "bifidus factors," or human milk glycans were found to promote the growth of intestinal Bifidobacterial species and were specifically found in the stool of breast-fed infants compared with formula-fed infants.
[0022] HMOs are composed of five monosaccharides: glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and sialic acid (Sia), with N-acetylneuraminic acid (Neu5Ac) being the predominant, if not exclusively, form of Sia. More than 200 different HMOs have been identified to date. The most important are 2'-fucosyllactose (2'FL), lacto-N-neotetraose (LNnT), 3-fucosyllactose (3FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP I), 3'sialyllactose sodium salt (3'SL), 6'sialyllactose sodium salt (6'SL), and lacto-N-tetraose (LNT).
[0023] HMOs can be isolated from breast milk or can be produced chemically or biochemically. HMOs are commercially available from a variety of manufacturers.
[0024] For purposes of the present invention, the source of the HMO is not critical. It will be apparent that HMOs from a variety of sources can be used.
[0025] Several studies have reported health benefits of HMOs, including modulation of the gut microbiota, anti-adhesion effects against pathogens, modulation of intestinal epithelial cell responses, and immune system development.
[0026] Thus, HMOs have highly beneficial effects when consumed by humans and / or animals.
[0027] In an embodiment of the present invention, HMOs not only serve as binders that have a favorable effect on the properties of compressed tablets, but also have a highly favorable effect when consumed by humans and / or animals.
[0028] Thus, the present invention relates to a compressed tablet (CT3) in which the HMO is a compressed tablet (CT), (CT1), (CT1'), (CT2) or (CT2') selected from the group consisting of 2'-fucosyllactose (2'FL), lacto-N-neotetraose (LNnT), 3-fucosyllactose (3FL), difucosyl-lactose (DFL), lacto-N-fucopentaose I (LNFP I), 3' sialyllactose sodium salt (3'SL), 6' sialyllactose sodium salt (6'SL), and lacto-N-tetraose (LNT).
[0029] Thus, the present invention relates to a compressed tablet (CT3') which is a compressed tablet (CT), (CT1), (CT1'), (CT2) or (CT2') in which the HMO is selected from the group consisting of 2'-fucosyllactose (2'FL), lacto-N-neotetraose (LNnT), 3-fucosyllactose (3FL), difucosyl-lactose (DFL), lacto-N-fucopentaose I (LNFP I), and lacto-N-tetraose (LNT).
[0030] Thus, the present invention relates to a compressed tablet (CT3'') which is a compressed tablet (CT), (CT1), (CT1'), (CT2) or (CT2') in which the HMO is selected from the group consisting of 2'-fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT).
[0031] Thus, the present invention relates to a compressed tablet (CT3'''), which is a compressed tablet (CT), (CT1), (CT1'), (CT2) or (CT2'), in which the HMO is lacto-N-neotetraose (LNnT).
[0032] In the compressed tablets according to the invention, the amount of at least one HMO is 1 to 60 wt-% based on the total weight of the compressed tablet (preferably 2 to 55 wt-%, more preferably 3 to 40 wt-%, and especially preferred 5 to 25 wt-% based on the total weight of the compressed tablet).
[0033] It is clear that the wt-% in a compressed tablet will always add up to 100.
[0034] Thus, the present invention relates to a compressed tablet (CT4), which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3'') or (CT3'''), in which the content of at least one HMO is 1 to 60 wt-% based on the total weight of the compressed tablet.
[0035] Thus, the present invention relates to a compressed tablet (CT4') which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3'') or (CT3''') in which the content of at least one HMO is 2 to 55 wt-% based on the total weight of the compressed tablet.
[0036] Thus, the present invention relates to a compressed tablet (CT4"), which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3") or (CT3'"), wherein the content of at least one HMO is 3 to 40 wt-% based on the total weight of the compressed tablet.
[0037] Thus, the present invention relates to a compressed tablet (CT4'''), which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3'') or (CT3'''), in which the content of at least one HMO is 5 to 25 wt-% based on the total weight of the compressed tablet.
[0038] Compressed tablets according to the present invention may also contain additional active ingredients (next to the HMO), such as vitamins, nutritional lipids, carotenoids, minerals, nutraceuticals, glycosaminoglycans or active members thereof, amino acids, or combinations thereof, and any other type of dietary ingredient useful in human or animal nutrition.
[0039] These ingredients can be present in amounts up to 60 wt-% based on the total weight of the compressed tablet, preferably in amounts of 3-30 wt-% based on the total weight of the compressed tablet.
[0040] The further active ingredients may be added per se and / or as a formulation.
[0041] Thus, the present invention relates to a compressed tablet (CT5) which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3"), (CT3'"), (CT4), (CT4'), (CT4") or (CT4'") which when compressed comprises at least one further active ingredient (next to the HMO).
[0042] Thus, the present invention relates to a compressed tablet (CT5') which is a compressed tablet (CT5) in which at least one further active ingredient is selected from the group consisting of vitamins, nutritional lipids, carotenoids, minerals, nutritional supplements, glycosaminoglycans or active members thereof and amino acids, and any other type of dietary ingredient.
[0043] Thus, the present invention relates to a compressed tablet (CT5';), which is a compressed tablet (CT5) in which at least one further active ingredient is selected from the group consisting of vitamins, minerals, glycosaminoglycans and active members thereof.
[0044] Thus, the present invention relates to a compressed tablet (CT5'"), (CT5') or (CT5"), wherein the amount of at least one further active ingredient is up to 60 wt-% based on the total weight of the compressed tablet.
[0045] Thus, the present invention relates to a compressed tablet (CT5''"), (CT5') or (CT5"), wherein the amount of at least one further active ingredient is 3 to 30 wt-% based on the total weight of the compressed tablet.
[0046] The compressed tablets of the present invention may contain any commonly known and commonly used additives commonly used in the manufacture of compressed tablets, such as fillers, flow aids, sweeteners, flavoring agents, disintegrants, preservatives, lubricants, and anti-adherents. Such ingredients are useful for improving the manufacturability, texture, and appearance of the product. Those skilled in the art will be familiar with such additives for inactive ingredients.
[0047] Such additional ingredients may be present in an amount of up to 98 wt-% based on the total weight of the compressed tablet (preferably 3 to 60 wt-%, more preferably 5 to 50 wt-%, based on the total weight of the compressed tablet).
[0048] Thus, the present invention relates to a compressed tablet (CT6), which is a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3"), (CT3'"), (CT4), (CT4'), (CT4"), (CT4'"), (CT5), (CT5'), (CT5"), (CT5'") or (CT5""), comprising at least one auxiliary agent.
[0049] Therefore, the present invention relates to a compressed tablet (CT6'), which is a compressed tablet (CT6) comprising at least one excipient selected from the group consisting of a filler, a flow aid, a sweetener, a flavoring agent, a disintegrant, a preservative, a lubricant, and an anti-adherent.
[0050] Thus, the present invention relates to a compressed tablet (CT6''), which is a compressed tablet (CT6) or (CT6'), in which the amount of at least one auxiliary agent is up to 98 wt-% based on the total weight of the compressed tablet.
[0051] Therefore, the present invention relates to a compressed tablet (CT6''), which is a compressed tablet (CT6) or (CT6'), in which the amount of at least one auxiliary agent is 3 to 60 wt-% based on the total weight of the compressed tablet.
[0052] Therefore, the present invention relates to a compressed tablet (CT6''''), which is a compressed tablet (CT6) or (CT6'), in which the amount of at least one auxiliary agent is 5 to 50 wt-% based on the total weight of the compressed tablet.
[0053] As stated above, it is clear that the wt-% of a compressed tablet will always add up to 100.
[0054] The size and shape of the compressed tablet is not critical. The compressed tablet can have any commonly used shape and size. In the context of the present invention, size is defined as the diameter of the longest dimension.
[0055] Compressed tablets usually have a disc-like shape. They can also be oval or of any desired shape.
[0056] The size of compressed tablets is usually such that they can be easily swallowed or chewed.
[0057] The typical size (diameter) of a disc-shaped compressed tablet is 3 to 20 mm. The height of the tablet depends on the tablet weight and the compression force applied during its production.
[0058] The total weight of the compressed tablet can also vary, usually between 0.2 and 5 g.
[0059] Additionally, although not required, compressed tablets according to the present invention can be coated.
[0060] The coated tablets according to the present invention can be stored in any known package (blister, container, bag, etc.) If desired, the compressed tablets can also be individually wrapped.
[0061] The process of manufacturing compressed tablets is carried out using conventional methods. In the context of the present invention, a rotary tablet press is used. Such devices are commercially available from various suppliers. The one used in all examples of the present invention is a PICCOLA CLASSIC "B" type rotary tablet press (manufactured by SMI).
[0062] The hardness of the compressed tablet is between 2 kp and 45 kp (as measured with a Sotax HT1 hardness tester (manufactured by SOTAX)). Preferably, the hardness of the compressed tablet is between 5 kp and 45 kp.
[0063] All hardness values in this patent application are measured with a Sotax HT1 hardness tester.
[0064] Accordingly, the present invention relates to a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3"), (CT3'"), (CT3'"), (CT4), (CT4'), (CT4"), (CT4'"), (CT4'"), (CT5), (CT5'), (CT5"), (CT5'"), (CT5""), (CT5""), (CT6), (CT6'), (CT6") or (CT6'"), having a hardness of between 2 kp and 45 kp (as measured with a Sotax HT1 hardness tester (manufactured by SOTAX).
[0065] Accordingly, the present invention relates to a compressed tablet (CT), (CT1), (CT1'), (CT2), (CT2'), (CT3), (CT3'), (CT3"), (CT3'"), (CT4), (CT4'), (CT4"), (CT4'"), (CT4'"), (CT5), (CT5'), (CT5"), (CT5'"), (CT5""), (CT5""), (CT6), (CT6'), (CT6") or (CT6'"), having a hardness of between 5 kp and 45 kp (as measured with a Sotax HT1 hardness tester (manufactured by SOTAX).
[0066] The following examples serve to illustrate the invention.
[0067] [Example] General Procedure for all Examples: 1. Weigh out all ingredients according to the working recipe. 2. Pass all ingredients (except premix) through a 20 mesh screen. 3. Add all ingredients except magnesium stearate to a V-blender and blend for 10-15 minutes. 4. Add the sieved magnesium stearate to step 3 and blend for 2-5 minutes. 5. Tablets are manufactured on a Piccola "B" type rotary tablet press (manufactured by RIVA) equipped with 0.5 inch circular standard concave tooling. Tablet hardness was measured with a Sotax HT1 hardness tester.
[0068] [Examples 1 to 12:]
[0069] [Table 1]
[0070] [Table 2]
[0071] As seen in Table 1, five batches of tablets (Examples 1-5) were produced using the same basic formula and the same tooling (0.5" round standard concave) on the same rotary tablet press (Piccola "B" tablet press). Examples 1, 2, and 3 are comparative placebo (HMO-free) batches with different sorbitol usage rates.
[0072] Table 2 shows that tablet hardness increases with increasing sorbitol in the tablet. Example 4 used 210.0 mg of HMO LNnT per tablet. Example 4 used the same base as Example 1, but the tablet hardness increased more than two-fold compared to Example 1 when compressed at the same compression force. The tablet hardness of Example 4 is also significantly higher than that of Example 3, which has the same tablet weight as Example 4 and more sorbitol in the formulation (up to QS). Example 5 contains HMO2'FL and also used the same base as Example 1. The tablet hardness of Example 5 is higher than that of Example 1.
[0073] [Table 3]
[0074] [Table 4]
[0075] [Table 5]
[0076] [Table 6]
[0077] As can be seen in Tables 3-6, seven batches of tablets (Examples 6-12) were produced using the same basic formula and the same tooling (0.5" round standard concave) on the same rotary tablet press (Piccola "B" tablet press). Unlike the examples in Tables 1 and 2, all seven examples have multivitamins, minerals, carotenoids, and other dietary ingredients (in this case, melatonin) in the formulation. Examples 6-9 do not have an HMO in the formulation (comparative examples). Examples 7 and 8 have more sorbitol (mg / tablet) in the formulation than Example 6. Example 9 has 210.0 mg / tablet more microcrystalline cellulose than Example 6 and the same tablet weight as Example 8. Examples 7, 8, and 9 show higher tablet hardness than Example 6 with increasing binder (sorbitol and / or microcrystalline cellulose). Examples 10, 11, and 12 have the same basic formula as Example 6. Example 12 has 210.0 mg / tablet of HMO2'FL in the formulation and shows higher hardness than Example 6. Examples 10 and 11 have 105.0 mg / tablet and 210.0 mg / tablet of HMO2'FL in the formulation, respectively. LNnT. Despite the lower amount of HMO LNnT, Example 10 has a significantly higher hardness than Example 6. Example 11 has a higher hardness than all other tablets in this series. For example, the tablet of Example 11 has a hardness of 40.1 kp when compressed at 3000 lbs, while the tablet of Example 6 has a hardness of only 17.4 kp, and Examples 8 and 9 have hardnesses of 26.5 kp and 24.9 kp, respectively, when compressed at 3000 lbs. As mentioned, the good binding ability of HMO helps achieve good tablet hardness even with lower amounts of binders such as sorbitol and microcrystalline cellulose. Furthermore, the addition of HMO can significantly reduce the compression force when a certain tablet hardness is desired. For example, if a tablet hardness of approximately 16 kp needs to be achieved, Example 11 (210.0 mg / tablet of HMO) can be used. The examples (with LNnT) require only 1500 lbs of compression force, whereas the following compression forces are required: 2500-3000 lbs for Example 6, 2000-2500 lbs for Example 7, and 2000 lbs for Examples 8 and 9.
Claims
1. A compressed tablet comprising: (i) at least one binder; (ii) at least 1 wt-% of at least one HMO, based on the total weight of the compressed tablet; and (iii) optionally, at least one further active ingredient; and having a hardness of at least 2 kp.
2. 2. The compressed tablet of claim 1, wherein the at least one binder is selected from the group consisting of sugars and their derivatives, proteins, synthetic polymers, and mineral type binders.
3. 3. The compressed tablet of claim 1 or 2, wherein the at least one binder is selected from the group consisting of disaccharides, polysaccharides and their derivatives, sugar alcohols, gelatin, polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) and mineral type binders.
4. The compressed tablet of any one of claims 1 to 3, wherein the amount of the at least one binder is from 0.5 to 98 wt-%, based on the total weight of the compressed tablet.
5. 5. The compressed tablet of any one of claims 1 to 4, wherein the HMO is selected from the group consisting of 2'-fucosyllactose (2'FL), lacto-N-neotetraose (LNnT), 3-fucosyllactose (3FL), difucosyl-lactose (DFL), lacto-N-fucopentaose I (LNFP I), 3' sialyllactose sodium salt (3'SL), 6' sialyllactose sodium salt (6'SL), and lacto-N-tetraose (LNT).
6. The compressed tablet of any one of claims 1 to 5, wherein the HMO is selected from the group consisting of 2'-fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT).
7. The compressed tablet according to any one of claims 1 to 6, wherein the content of the at least one HMO is from 1 to 60 wt-%, based on the total weight of the compressed tablet.
8. The compressed tablet according to any one of claims 1 to 6, wherein the content of the at least one HMO is from 2 to 55 wt-%, based on the total weight of the compressed tablet.
9. A compressed tablet according to any one of claims 1 to 8, comprising (next to the HMO) at least one further active ingredient.
10. 10. The compressed tablet of claim 9, wherein the at least one additional active ingredient is selected from the group consisting of vitamins, nutritional lipids, carotenoids, minerals, nutraceuticals, glycosaminoglycans or active members thereof and amino acids, and any other type of dietary ingredient.
11. 11. The compressed tablet of claim 9 or 10, wherein the amount of the at least one additional active ingredient is up to 60 wt-%, based on the total weight of the compressed tablet.
12. The compressed tablet according to any one of claims 1 to 11, comprising at least one auxiliary agent.
13. 13. The compressed tablet of claim 12, further comprising at least one excipient selected from the group consisting of fillers, sweeteners, flow aids, flavoring agents, disintegrants, preservatives, lubricants, and anti-adherents.
